VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.50 price objective on shares of VolitionRx in a research report on Wednesday, March 27th.

VolitionRx Stock Up 1.4 %

Shares of NYSE VNRX opened at $0.89 on Friday. VolitionRx has a 12-month low of $0.55 and a 12-month high of $2.09. The firm’s 50-day simple moving average is $0.83 and its 200 day simple moving average is $0.85. The company has a market cap of $73.12 million, a price-to-earnings ratio of -1.75 and a beta of 1.26.

VolitionRx (NYSE:VNRX) last announced its earnings results on Monday, March 25th. The company reported ($0.11) earnings per share for the quarter. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.50 million. On average, equities analysts expect that VolitionRx will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new position in shares of VolitionRx Limited (NYSE:VNRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx at the end of the most recent quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.